{"id":8087,"date":"2026-11-19T10:05:07","date_gmt":"2026-11-19T09:05:07","guid":{"rendered":"https:\/\/lenus-healthcare.com\/?p=8087"},"modified":"2026-11-19T10:16:58","modified_gmt":"2026-11-19T09:16:58","slug":"gazyva-supplier","status":"publish","type":"post","link":"https:\/\/lenus-healthcare.com\/en\/gazyva-supplier\/","title":{"rendered":"Gazyva (obinutuzumab): First FDA-Approved Drug for Adults With Primary Membranous Nephropathy"},"content":{"rendered":"<p>Primary membranous nephropathy (pMN) is a rare kidney disease in which the immune system attacks the glomeruli, the tiny filters that remove waste from the blood. The glomeruli become inflamed and damaged and leak large amounts of protein into the urine. Complications can include high cholesterol, high blood pressure, severe swelling, fatigue, and kidney failure.<\/p>\n<p>On November 13, 2026, the U.S. Food and Drug Administration (FDA) announced the approval of Gazyva (obinutuzumab) injection for adults with primary membranous nephropathy who are at risk of disease progression, to induce remission of proteinuria (protein in the urine). The FDA states that this is the first drug approved specifically for the treatment of adults with pMN.<\/p>\n<blockquote><p><a href=\"https:\/\/lenus-healthcare.com\/en\/contact-us\/#form-contact\"><strong>For international supply and commercial inquiries regarding this type of product, please contact the Lenus Health sales team.<\/strong><\/a><\/p><\/blockquote>\n<p><strong>Table of Contents<\/strong><\/p>\n<ol>\n<li><a href=\"#Introduction\">Introduction to Gazyva and Primary Membranous Nephropathy<\/a><\/li>\n<li><a href=\"#Clinical\">Clinical Trial<\/a><\/li>\n<li><a href=\"#Dosage\">Dosage and Administration<\/a><\/li>\n<li><a href=\"#Common\">Common Adverse Reactions<\/a><\/li>\n<li><a href=\"#Warnings\">Warnings<\/a><\/li>\n<li><a href=\"#FDA\">FDA Designations and Expedited Programs<\/a><\/li>\n<li><a href=\"#conclusion\">Conclusion and Future Perspectives<\/a><\/li>\n<li><a href=\"#faq\">Frequently Asked Questions<\/a><\/li>\n<\/ol>\n<h2 id=\"Introduction\">1. Introduction to Gazyva and Primary Membranous Nephropathy<\/h2>\n<p>Gazyva is an injection approved by the FDA for adults with pMN at risk of disease progression, to induce remission of proteinuria. Gazyva was previously approved for certain cancers, active lupus nephritis, and childhood-onset idiopathic nephrotic syndrome.<\/p>\n<p><img decoding=\"async\" src=\"\/wp-content\/uploads\/2026\/11\/gazyva-supplier00.jpg\" alt=\"Clinical Trial-Gazyva Supplier\" width=\"100%\" height=\"auto\" \/><\/p>\n<h2 id=\"Clinical\">2. Clinical Trial<\/h2>\n<p>The approval was based on the MAJESTY study (NCT04629248), a Phase 3, randomized, controlled, open-label, multicenter trial in 142 adults with pMN. The comparator was tacrolimus, which is sometimes used off-label for pMN.<\/p>\n<p>The main study period was 104 weeks. The primary endpoint was complete remission of proteinuria, defined as a urine protein-creatinine ratio (UPCR) of no more than 0.3 g\/g with stable estimated glomerular filtration rate (eGFR) at Week 104, without rescue therapy, treatment failure, or early discontinuation. Complete remission at Week 104 was 36% in the Gazyva group versus 6% in the tacrolimus group. The FDA describes this difference as statistically significant.<\/p>\n<h2 id=\"Dosage\">3. Dosage and Administration<\/h2>\n<p>The FDA announcement does not state dosing or administration details. For complete prescribing information, refer to the official FDA product label.<\/p>\n<h2 id=\"Common\">4. Common Adverse Reactions<\/h2>\n<p>The most common adverse reactions reported in the pMN study were:<\/p>\n<ul>\n<li>Infusion-related reactions<\/li>\n<li>Upper respiratory tract infection<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"\/wp-content\/uploads\/2026\/11\/gazyva-supplier01.jpg\" alt=\"Warnings-Gazyva Supplier\" width=\"100%\" height=\"auto\" \/><\/p>\n<h2 id=\"Warnings\">5. Warnings<\/h2>\n<p>Gazyva carries a boxed warning for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy (PML), a rare and serious brain infection that occurs in people with a weakened immune system. Other warnings, such as additional infection and infusion reaction warnings, are not detailed in the FDA announcement; refer to the prescribing information.<\/p>\n<h2 id=\"FDA\">6. FDA Designations and Expedited Programs<\/h2>\n<p>This use of Gazyva received Breakthrough Therapy, Orphan Drug, and Priority Review designations.<\/p>\n<p>&nbsp;<\/p>\n<p><strong id=\"conclusion\">7. Conclusion and Future Perspectives<\/strong><\/p>\n<p>The approval of Gazyva provides the first FDA-approved drug option for adults with pMN. Because the drug carries a boxed warning, treatment decisions require careful physician assessment and review of the prescribing information.<\/p>\n<blockquote><p><a href=\"https:\/\/lenus-healthcare.com\/en\/contact-us\/#form-contact\"><strong>For international supply and commercial inquiries regarding this type of product, please contact the Lenus Health sales team.<\/strong><\/a><\/p><\/blockquote>\n<p><strong id=\"faq\">8. Frequently Asked Questions<\/strong><\/p>\n<ul>\n<li><strong>Who is eligible for Gazyva therapy for pMN?<br \/>\n<\/strong>Adults with primary membranous nephropathy at risk of disease progression, to induce remission of proteinuria.<\/li>\n<li><strong>What were the results of the MAJESTY trial?<br \/>\n<\/strong>In 142 adults, complete remission of proteinuria at Week 104 occurred in 36% of Gazyva patients versus 6% of tacrolimus patients.<\/li>\n<li><strong>What are the most common side effects?<br \/>\n<\/strong>Infusion-related reactions and upper respiratory tract infection.<\/li>\n<li><strong>Does Gazyva have a boxed warning?<br \/>\n<\/strong>Yes: hepatitis B virus reactivation and PML.<\/li>\n<li><strong>What is the Gazyva dose?<br \/>\n<\/strong>The FDA announcement does not state dosing. Refer to the official product label.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>pMN Therapy Sourcing<\/p>\n","protected":false},"author":2,"featured_media":8089,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_joinchat":[],"footnotes":""},"categories":[120],"tags":[],"class_list":["post-8087","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-new-medicine"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gazyva Supplier | pMN Therapy Sourcing | Lenus Health<\/title>\n<meta name=\"description\" content=\"Gazyva Supplier | FDA-approved obinutuzumab for primary membranous nephropathy, sourced internationally by Lenus Health.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lenus-healthcare.com\/en\/gazyva-supplier\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gazyva Supplier | pMN Therapy Sourcing | Lenus Health\" \/>\n<meta property=\"og:description\" content=\"Gazyva Supplier | FDA-approved obinutuzumab for primary membranous nephropathy, sourced internationally by Lenus Health.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lenus-healthcare.com\/en\/gazyva-supplier\/\" \/>\n<meta property=\"og:site_name\" content=\"Lenus Health\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-19T09:05:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-19T09:16:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2026\/11\/gazyva-supplierTH.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"873\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"login-hashemzadeh-dash\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"login-hashemzadeh-dash\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/gazyva-supplier\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/gazyva-supplier\\\/\"},\"author\":{\"name\":\"login-hashemzadeh-dash\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/#\\\/schema\\\/person\\\/0abed38587372602833862aaf8e51e09\"},\"headline\":\"Gazyva (obinutuzumab): First FDA-Approved Drug for Adults With Primary Membranous Nephropathy\",\"datePublished\":\"2026-11-19T09:05:07+00:00\",\"dateModified\":\"2026-11-19T09:16:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/gazyva-supplier\\\/\"},\"wordCount\":582,\"publisher\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/gazyva-supplier\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lenus-healthcare.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/gazyva-supplierTH.jpg\",\"articleSection\":[\"New medicines\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/gazyva-supplier\\\/\",\"url\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/gazyva-supplier\\\/\",\"name\":\"Gazyva Supplier | pMN Therapy Sourcing | Lenus Health\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/gazyva-supplier\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/gazyva-supplier\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lenus-healthcare.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/gazyva-supplierTH.jpg\",\"datePublished\":\"2026-11-19T09:05:07+00:00\",\"dateModified\":\"2026-11-19T09:16:58+00:00\",\"description\":\"Gazyva Supplier | FDA-approved obinutuzumab for primary membranous nephropathy, sourced internationally by Lenus Health.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/gazyva-supplier\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/gazyva-supplier\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/gazyva-supplier\\\/#primaryimage\",\"url\":\"https:\\\/\\\/lenus-healthcare.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/gazyva-supplierTH.jpg\",\"contentUrl\":\"https:\\\/\\\/lenus-healthcare.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/gazyva-supplierTH.jpg\",\"width\":1600,\"height\":873,\"caption\":\"pMN Therapy Sourcing\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/gazyva-supplier\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New medicines\",\"item\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/category\\\/new-medicine\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Gazyva (obinutuzumab): First FDA-Approved Drug for Adults With Primary Membranous Nephropathy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/\",\"name\":\"Lenus Health\",\"description\":\"Lenus Health Gmbh | Berlin\",\"publisher\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/#organization\",\"name\":\"Lenus Health\",\"alternateName\":\"Lenus Healthcare\",\"url\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/lenus-healthcare.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/Logo-pur-fav.webp\",\"contentUrl\":\"https:\\\/\\\/lenus-healthcare.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/Logo-pur-fav.webp\",\"width\":1275,\"height\":298,\"caption\":\"Lenus Health\"},\"image\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/79452169\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/#\\\/schema\\\/person\\\/0abed38587372602833862aaf8e51e09\",\"name\":\"login-hashemzadeh-dash\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g\",\"caption\":\"login-hashemzadeh-dash\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gazyva Supplier | pMN Therapy Sourcing | Lenus Health","description":"Gazyva Supplier | FDA-approved obinutuzumab for primary membranous nephropathy, sourced internationally by Lenus Health.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lenus-healthcare.com\/en\/gazyva-supplier\/","og_locale":"en_US","og_type":"article","og_title":"Gazyva Supplier | pMN Therapy Sourcing | Lenus Health","og_description":"Gazyva Supplier | FDA-approved obinutuzumab for primary membranous nephropathy, sourced internationally by Lenus Health.","og_url":"https:\/\/lenus-healthcare.com\/en\/gazyva-supplier\/","og_site_name":"Lenus Health","article_published_time":"2026-11-19T09:05:07+00:00","article_modified_time":"2026-11-19T09:16:58+00:00","og_image":[{"width":1600,"height":873,"url":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2026\/11\/gazyva-supplierTH.jpg","type":"image\/jpeg"}],"author":"login-hashemzadeh-dash","twitter_card":"summary_large_image","twitter_misc":{"Written by":"login-hashemzadeh-dash","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lenus-healthcare.com\/en\/gazyva-supplier\/#article","isPartOf":{"@id":"https:\/\/lenus-healthcare.com\/en\/gazyva-supplier\/"},"author":{"name":"login-hashemzadeh-dash","@id":"https:\/\/lenus-healthcare.com\/en\/#\/schema\/person\/0abed38587372602833862aaf8e51e09"},"headline":"Gazyva (obinutuzumab): First FDA-Approved Drug for Adults With Primary Membranous Nephropathy","datePublished":"2026-11-19T09:05:07+00:00","dateModified":"2026-11-19T09:16:58+00:00","mainEntityOfPage":{"@id":"https:\/\/lenus-healthcare.com\/en\/gazyva-supplier\/"},"wordCount":582,"publisher":{"@id":"https:\/\/lenus-healthcare.com\/en\/#organization"},"image":{"@id":"https:\/\/lenus-healthcare.com\/en\/gazyva-supplier\/#primaryimage"},"thumbnailUrl":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2026\/11\/gazyva-supplierTH.jpg","articleSection":["New medicines"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/lenus-healthcare.com\/en\/gazyva-supplier\/","url":"https:\/\/lenus-healthcare.com\/en\/gazyva-supplier\/","name":"Gazyva Supplier | pMN Therapy Sourcing | Lenus Health","isPartOf":{"@id":"https:\/\/lenus-healthcare.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lenus-healthcare.com\/en\/gazyva-supplier\/#primaryimage"},"image":{"@id":"https:\/\/lenus-healthcare.com\/en\/gazyva-supplier\/#primaryimage"},"thumbnailUrl":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2026\/11\/gazyva-supplierTH.jpg","datePublished":"2026-11-19T09:05:07+00:00","dateModified":"2026-11-19T09:16:58+00:00","description":"Gazyva Supplier | FDA-approved obinutuzumab for primary membranous nephropathy, sourced internationally by Lenus Health.","breadcrumb":{"@id":"https:\/\/lenus-healthcare.com\/en\/gazyva-supplier\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lenus-healthcare.com\/en\/gazyva-supplier\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lenus-healthcare.com\/en\/gazyva-supplier\/#primaryimage","url":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2026\/11\/gazyva-supplierTH.jpg","contentUrl":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2026\/11\/gazyva-supplierTH.jpg","width":1600,"height":873,"caption":"pMN Therapy Sourcing"},{"@type":"BreadcrumbList","@id":"https:\/\/lenus-healthcare.com\/en\/gazyva-supplier\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/lenus-healthcare.com\/en\/"},{"@type":"ListItem","position":2,"name":"New medicines","item":"https:\/\/lenus-healthcare.com\/en\/category\/new-medicine\/"},{"@type":"ListItem","position":3,"name":"Gazyva (obinutuzumab): First FDA-Approved Drug for Adults With Primary Membranous Nephropathy"}]},{"@type":"WebSite","@id":"https:\/\/lenus-healthcare.com\/en\/#website","url":"https:\/\/lenus-healthcare.com\/en\/","name":"Lenus Health","description":"Lenus Health Gmbh | Berlin","publisher":{"@id":"https:\/\/lenus-healthcare.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lenus-healthcare.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/lenus-healthcare.com\/en\/#organization","name":"Lenus Health","alternateName":"Lenus Healthcare","url":"https:\/\/lenus-healthcare.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lenus-healthcare.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2025\/07\/Logo-pur-fav.webp","contentUrl":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2025\/07\/Logo-pur-fav.webp","width":1275,"height":298,"caption":"Lenus Health"},"image":{"@id":"https:\/\/lenus-healthcare.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/79452169"]},{"@type":"Person","@id":"https:\/\/lenus-healthcare.com\/en\/#\/schema\/person\/0abed38587372602833862aaf8e51e09","name":"login-hashemzadeh-dash","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g","caption":"login-hashemzadeh-dash"}}]}},"_links":{"self":[{"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/posts\/8087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/comments?post=8087"}],"version-history":[{"count":4,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/posts\/8087\/revisions"}],"predecessor-version":[{"id":8103,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/posts\/8087\/revisions\/8103"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/media\/8089"}],"wp:attachment":[{"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/media?parent=8087"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/categories?post=8087"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/tags?post=8087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}